Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
1.
Arch Dermatol Res ; 315(4): 895-902, 2023 May.
Article in English | MEDLINE | ID: mdl-36394635

ABSTRACT

BACKGROUND: The human leukocyte antigen system (HLA) is divided into two classes involved in antigen presentation: class I presenting intracellular antigens and class II presenting extracellular antigens. While susceptibility to infections is correlated with the HLA system, data on associations between HLA genotypes and Malassezia-related skin diseases (MRSD) are lacking. Thus, the objective of this study was to investigate associations between HLA alleles and MRSD. MATERIALS AND METHODS: Participants in The Danish Blood Donor Study (2010-2018) provided questionnaire data on life style, anthropometric measures, and registry data on filled prescriptions. Genotyping was done using Illumina Infinium Global Screening Array, and HLA alleles were imputed using the HIBAG algorithm. Cases and controls were defined using filled prescriptions on topical ketoconazole 2% as a proxy of MRSD. Logistic regressions assessed associations between HLA alleles and MRSD adjusted for confounders and Bonferroni corrected for multiple tests. RESULTS: A total of 9455 participants were considered MRSD cases and 24,144 participants as controls. We identified four risk alleles B*57:01, OR 1.19 (95% CI: 1.09-1.31), C*01:02, OR 1.19 (95% CI: 1.08-1.32), C*06:02, OR 1.14 (95% CI: 1.08-1.22), and DRB1*01:01, OR 1.10 (95% CI: 1.04-1.17), and two protective alleles, DQB1*02:01, OR 0.89 (95% CI: 0.85-0.94), and DRB1*03:01, OR 0.89 (95% CI: 0.85-0.94). CONCLUSION: Five novel associations between HLA alleles and MRSD were identified in our cohort, and one previous association was confirmed. Future studies should assess the correlation between Malassezia antigens and antigen-binding properties of the associated HLA alleles.


Subject(s)
Dermatomycoses , HLA Antigens , Malassezia , Malassezia/genetics , Dermatomycoses/blood , Dermatomycoses/genetics , HLA Antigens/genetics , Skin Diseases, Genetic , Case-Control Studies , Denmark , Cohort Studies , Genotype , Alleles , Humans , Male , Female , Adult , Middle Aged , Blood Donors
2.
Mycoses ; 64(4): 340-348, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33217082

ABSTRACT

Dermatophyte infections usually present as various types of superficial cutaneous mycoses; on very rare occasions, dermatophytes enter deep into the dermis and cause invasive infections. In this study, we aimed to perform a systematic review of all reported invasive dermatophytosis cases over the past 20 years. We performed systematic searches in PubMed/Medline, EMBASE and Web of Science and identified 123 papers reporting 160 individual cases of invasive dermatophytosis between 2000 and 2020. Our study included 103 (64.4%) males, and the mean age at diagnosis was 43.0 years (range: 3-87 years). The most common predisposing factor was superficial dermatophytosis (56.9%), followed by solid organ transplantation (26.9%), the use of topical immunosuppressants (15.6%), gene mutations (14.4%), diabetes (14.4%) and trauma (6.9%). Trichophyton (T.) rubrum was the most prevalent pathogen (53.1%) responsible for invasive dermatophytosis, followed by T. mentagrophytes (7.5%), Microsporum canis (6.9%), T. tonsurans (5.6%), T. interdigitale (5.0%) and T. violaceum (3.8%). Patients with CARD9 or STAT3 mutations were prone to have mixed infection of two or more dermatophytes, present with eosinophilia and high IgE, and develop disseminated infections. Overall mortality was 7.9%, and the mortality in patients with and without gene mutations was 17.4% and 5.5%, respectively. Most of the normal host patients responded well to oral antifungal agents, while gene-deficient patients usually required lifelong treatment to stabilise their infection status. Our review indicated the importance of preventive treatment of superficial tinea in patients with immunosuppression and gene deficiencies to avoid the development of invasive dermatophytosis.


Subject(s)
Dermatomycoses/blood , Dermatomycoses/prevention & control , Invasive Fungal Infections/prevention & control , Skin/microbiology , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Dermatomycoses/drug therapy , Dermatomycoses/mortality , Humans , Invasive Fungal Infections/drug therapy , Invasive Fungal Infections/mortality , Organ Transplantation/adverse effects , Risk Factors
3.
Pediatr Infect Dis J ; 39(5): 444-448, 2020 05.
Article in English | MEDLINE | ID: mdl-32118859

ABSTRACT

BACKGROUND: Malassezia pachydermatis is a rare cause of systemic infection in infants. METHODS: A total of 4 cases of M. pachydermatis fungemia that occurred in our neonatal intensive care unit over a 21-month period were reviewed, as well as 27 cases reported in the literature since 1988. RESULTS: The patients were preterm with multiple complications and had birth weights ranging from 490 to 810 g and gestational age between 23 and 26 weeks. All patients had received prophylactic fluconazole, broad-spectrum antibiotics and parenteral lipid supplements before fungemia onset, which occurred between the age of 7 and 28 days. Symptoms were nonspecific and thrombocytopenia was the primary laboratory finding. All patients received intravenous antifungal treatment and recovered from their infection. The 27 cases from review of the literature also indicated that the infected infants were extremely low birth weight (77.8%), with multiple underlying diseases (94.7%), receiving lipid-supplementation (100%) from a central vascular catheter. Most infants received antifungal treatment (73.1%) and catheter removal (73.1%) as the management. CONCLUSIONS: M. pachydermatis is a pathogenic agent that causes late onset sepsis in critically ill low birth weight infants with generally good outcomes. Targeted antifungal treatment as well as catheter removal appear to be key factors for infection management.


Subject(s)
Dermatomycoses/blood , Malassezia/pathogenicity , Sepsis/microbiology , Antifungal Agents/therapeutic use , Birth Weight , Case-Control Studies , Cross Infection , Dermatomycoses/drug therapy , Female , Fungemia/drug therapy , Gestational Age , Humans , Infant , Infant, Low Birth Weight , Infant, Newborn , Intensive Care Units, Neonatal , Male , Retrospective Studies , Sepsis/drug therapy
4.
Microb Pathog ; 139: 103921, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31830582

ABSTRACT

The delineation of the pathogenic interaction between the host skin immune responses and dermatophytes has remained indigent. The obscure enigma in host-dermatophyte immunopathogenic interactions is the T regulatory (Treg) and T-helper (Th) 17  cell role in maintaining immune homeostasis. We attempted to understand the regulation and recognition of lineage-specific response in chronic dermatophytic skin infection patients. The percentages of Th17 (CD4+CD161+IL23R+) and Treg (CD4+CD25+FoxP3+) cell subpopulations in the peripheral circulation of thirty chronic dermatophytic skin infection patients and twenty healthy individuals was determined. The serum cytokine levels were estimated for disease correlation. The mean duration of the disease was 10.68 ± 8.72 months, with Trichophyton mentagrophytes complex as the major pathogen. Total serum IgE level of patients was significantly higher compared to healthy controls (305 ± 117 vs 98.53 ± 54.55 IU/ml; p < 0.01). Expression of Th17 and Treg cell markers on CD4+ T cells was significantly elevated in patients than controls (p < 0.05). Comparatively, serum interleukin (IL)-4 and interferon (IFN)-γ levels were increased, with low IL-10 levels in patients. Our data envisages a complex immune dysfunction in chronic dermatophytosis, arising either as a result of dermatophyte exposure or paradoxical precedence of disease establishment. Designing new treatment strategies and preventing recurrences are challenges for future research.


Subject(s)
Arthrodermataceae/physiology , Dermatomycoses/immunology , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology , Adolescent , Adult , Chronic Disease , Dermatomycoses/blood , Dermatomycoses/microbiology , Female , Humans , Interferon-gamma/blood , Interleukin-10/blood , Interleukin-4/blood , Male , T-Lymphocytes, Regulatory/microbiology , Th17 Cells/microbiology , Young Adult
5.
JAMA Dermatol ; 154(12): 1409-1416, 2018 12 01.
Article in English | MEDLINE | ID: mdl-30347032

ABSTRACT

Importance: Terbinafine hydrochloride and griseofulvin are effective oral treatments for dermatophyte infections but have been associated with hepatic and hematologic abnormalities. The prevalence of alanine aminotransferase elevations, aspartate aminotransferase elevations, anemia, lymphopenia, and neutropenia among adults and children taking terbinafine and griseofulvin is unclear. Objective: To measure the rate of laboratory test result abnormalities in healthy adults and children taking terbinafine or griseofulvin for dermatophyte infections. Design, Setting, and Participants: This retrospective study assessed adults and children taking terbinafine or griseofulvin for dermatophyte infections from January 1, 2006, to December 31, 2016. Data were collected from one Midwest health care system. Exclusion criteria were preceding diagnosis of hepatic or hematologic condition and preceding or concurrent use of oral ketoconazole, amphotericin, or itraconazole. Main Outcomes and Measures: The rates of elevated alanine aminotransferase measurements, elevated aspartate aminotransferase measurements, anemia, lymphopenia, and neutropenia in adults and children taking terbinafine, griseofulvin microsize, or griseofulvin ultramicrosize were calculated. Secondary measures included rates of baseline abnormalities, frequency of laboratory test results that required additional testing or discontinued use of medication, and laboratory test result monitoring practices. Results: This study included laboratory data from 4985 patients (mean [SD] age, 42.8 [20.3] years; 2288 [45.9%] female) receiving 4309 courses of terbinafine, 634 courses of griseofulvin microsize, and 159 courses of griseofulvin ultramicrosize. We identified a low rate of laboratory test result abnormalities in patients taking terbinafine or griseofulvin. When laboratory test result abnormalities occurred, most were low grade (212 [93.4%] grade 1) and did not require subsequent laboratory test result evaluation or discontinued use of medication (15 051 [99.9%]). Elevations in alanine aminotransferase measurements were detected infrequently and were comparable to baseline detection rates (61 [3.5%] vs 95 [3.6%] for terbinafine, 2 [2.1%] vs 3 [3.7%] for griseofulvin microsize, and 0 vs 2 [5.0%] for griseofulvin ultramicrosize). Rates of elevated aspartate aminotransferase measurements, anemia, lymphopenia, and neutropenia were also infrequent and comparable to baseline rates. Conclusions and Relevance: In this study. the rates of alanine aminotransferase elevations, aspartate aminotransferase elevations, anemia, lymphopenia, and neutropenia in adults and children taking terbinafine or griseofulvin were low and equivalent to the baseline rates of abnormalities in this population. Routine interval laboratory test result monitoring appears to be unnecessary in adults and children without underlying hepatic or hematologic conditions taking terbinafine or griseofulvin for dermatophyte infections. Abandoning frequent laboratory monitoring can decrease unnecessary health care spending, decrease patient psychological angst associated with blood draws, and allow for expanded use of these effective oral medications.


Subject(s)
Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Dermatomycoses/blood , Griseofulvin/administration & dosage , Terbinafine/administration & dosage , Administration, Oral , Adolescent , Adult , Aged , Aged, 80 and over , Antifungal Agents/administration & dosage , Biomarkers/blood , Child , Child, Preschool , Dermatomycoses/drug therapy , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Young Adult
6.
Indian J Pathol Microbiol ; 61(1): 103-105, 2018.
Article in English | MEDLINE | ID: mdl-29567895

ABSTRACT

Mucormycosis is a relatively rare fungal infection seen in immunocompromised patients. Very few cases of invasive cutaneous mucormycosis occurring in neonates have been reported in literature. It is an aggressive disease with a mortality rate of around 64% in neonates, so a high index of suspicion is essential for rapid diagnosis and definitive treatment with broad-spectrum antifungals such as Amphotericin B. We present a case of a premature infant born at 25 weeks of gestation who developed vesicobullous lesions all over the body on day 5 of life. Biopsy from the vesicles confirmed the presence of angioinvasive fungal hyphae of mucormycosis which were highlighted on Periodic acid-Schiff and Grocott stain.


Subject(s)
Blister/microbiology , Dermatomycoses/diagnosis , Invasive Fungal Infections/diagnosis , Mucormycosis/blood , Mucormycosis/diagnosis , Amphotericin B/therapeutic use , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Biopsy , Blister/pathology , Dermatomycoses/blood , Dermatomycoses/microbiology , Humans , Immunocompromised Host , Infant, Newborn , Infant, Premature , Invasive Fungal Infections/drug therapy , Invasive Fungal Infections/microbiology , Male , Mucormycosis/microbiology , Risk Factors , Skin/microbiology , Skin/pathology
7.
J Mycol Med ; 28(2): 285-288, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29482975

ABSTRACT

PURPOSE: The aim of this study was to develop and evaluate the diagnostic potential of indirect enzyme-linked immunosorbent assay (I-ELISA) for the rapid and precise diagnosis of Microsporum canis infection in humans. BASIC PROCEDURES: The present study reports the production, partial purification and SDS-PAGE analysis of M. canis mycelial antigens and production of specific polyclonal antibodies. It also reports the development and optimization of indirect ELISA and evaluation of its potential for the diagnosis of M. canis infection in humans. MAIN FINDINGS: An I-ELISA showed the sensitivity of 94.55% and specificity of 93.33%. Positive and negative predictive values were 96.30% and 90.32% respectively. Receiver operating characteristic (ROC) curve analysis of the data showed higher diagnostic accuracy. The area under the curve (AUC) was 0.925. A significant correlation coefficient of 0.8771 (P<0.0001) was obtained between I-ELISA and fungal culture method. PRINCIPAL CONCLUSIONS: In conclusion, the present study clearly shows the detection of specific antibodies by indirect ELISA using M. canis antigens. The assay is sensitive, specific and easy to perform, could enable rapid and more convenient diagnosis of dermatophytosis in humans.


Subject(s)
Dermatomycoses/diagnosis , Enzyme-Linked Immunosorbent Assay/methods , Microsporum/isolation & purification , Serologic Tests/methods , Antigens, Fungal/immunology , Dermatomycoses/blood , Enzyme Assays/methods , Humans , Mycelium/immunology , ROC Curve , Sensitivity and Specificity
9.
Transpl Infect Dis ; 19(2)2017 Apr.
Article in English | MEDLINE | ID: mdl-28099778

ABSTRACT

Non-Candida opportunistic yeasts are emerging causes of bloodstream infection (BSI) in immunocompromised hosts. However, their clinical presentation, management, and outcomes in stem cell transplant (SCT) recipients are not well described. We report the first case to our knowledge of Pseudozyma BSI in a SCT recipient. He had evidence of cutaneous involvement, which has not been previously described in the literature. He became infected while neutropenic and receiving empiric micafungin, which is notable because Pseudozyma is reported to be resistant to echinocandins. He was successfully treated with the sequential use of liposomal amphotericin B and voriconazole. A review of the literature revealed nine reported instances of Pseudozyma fungemia. We performed a retrospective review of 3557 SCT recipients at our institution from January 2000 to June 2015 and identified four additional cases of non-Candida yeast BSIs. These include two with Cryptococcus, one with Trichosporon, and one with Saccharomyces. Pseudozyma and other non-Candida yeasts are emerging pathogens that can cause severe and disseminated infections in SCT recipients and other immunocompromised hosts. Clinicians should have a high degree of suspicion for echinocandin-resistant yeasts, if patients develop breakthrough yeast BSIs while receiving echinocandin therapy.


Subject(s)
Antifungal Agents/therapeutic use , Dermatomycoses/microbiology , Exanthema/microbiology , Fungemia/microbiology , Opportunistic Infections/microbiology , Ustilaginales/pathogenicity , Yeasts/pathogenicity , Adult , Amphotericin B/administration & dosage , Amphotericin B/therapeutic use , Antifungal Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Cryptococcus/isolation & purification , Cryptococcus/pathogenicity , Cytarabine/therapeutic use , Dermatomycoses/blood , Dermatomycoses/drug therapy , Dermatomycoses/pathology , Echinocandins/administration & dosage , Echinocandins/therapeutic use , Exanthema/blood , Exanthema/drug therapy , Exanthema/pathology , Fever/microbiology , Fungemia/drug therapy , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Idarubicin/therapeutic use , Immunocompromised Host , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Lipopeptides/administration & dosage , Lipopeptides/therapeutic use , Male , Micafungin , Opportunistic Infections/blood , Opportunistic Infections/drug therapy , Retrospective Studies , Saccharomyces/isolation & purification , Saccharomyces/pathogenicity , Salvage Therapy/methods , Trichosporon/isolation & purification , Trichosporon/pathogenicity , Ustilaginales/isolation & purification , Vidarabine/analogs & derivatives , Vidarabine/therapeutic use , Voriconazole/administration & dosage , Voriconazole/therapeutic use , Yeasts/isolation & purification
10.
Am J Vet Res ; 78(1): 90-99, 2017 Jan.
Article in English | MEDLINE | ID: mdl-28029293

ABSTRACT

OBJECTIVE To determine the pharmacokinetics of terbinafine in little brown myotis (Myotis lucifugus) infected with Pseudogymnoascus destructans. ANIMALS 123 bats from a P destructans-infected hibernation site in Virginia. PROCEDURES 3 bats were euthanized and necropsied to confirm the presence of P destructans within the population. The remaining 120 bats were systematically assigned to 6 groups (20 bats/group). Bats in each of 3 groups received 6, 20, or 60 mg of terbinafine/kg, SC, once daily for 10 days. Bats in another group received 200 mg of terbinafine/kg, SC, once daily for 5 days. Bats in 1 group received the terbinafine vehicle solution (0.1 mL/kg, SC, once daily for 10 days). Bats in the remaining group did not receive any treatment. Following the treatment period (days 1 through 10), bats were housed in a hibernation chamber and monitored daily until euthanasia on day 42, 75, or 109. Tissue specimens were collected from all bats as soon as possible after death or euthanasia to determine terbinafine concentration. Within each group and tissue type, terbinafine concentration data were pooled, and pharmacokinetic parameters were calculated by noncompartmental methods. RESULTS Adverse neurologic effects and a high mortality rate before day 10 were observed in bats that received the highest terbinafine dose (200 mg/kg) but not those that received lower doses. Presumed therapeutic terbinafine concentrations (≥ 2 µg/g) were maintained in skin and wing for at least 30 and 6 days in bats that received the 60 and 20 mg/kg doses, respectively, but were not achieved in most bats that received the 6 mg/kg dose. Tissue terminal half-life ranged from 14 to 22 days. Terbinafine concentration in hair was positively correlated with that in skin and wing. CONCLUSIONS AND CLINICAL RELEVANCE Results indicated terbinafine doses > 6 but < 200 mg/kg should be further evaluated for the treatment of P destructans-infected bats. Collection of serial hair specimens may represent a noninvasive method for monitoring terbinafine concentration in treated bats.


Subject(s)
Antifungal Agents/pharmacokinetics , Ascomycota , Chiroptera/metabolism , Dermatomycoses/veterinary , Naphthalenes/pharmacokinetics , Animals , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Dermatomycoses/blood , Dermatomycoses/drug therapy , Dermatomycoses/mortality , Half-Life , Hibernation , Naphthalenes/administration & dosage , Naphthalenes/therapeutic use , Terbinafine , Virginia
11.
Mycoses ; 60(3): 178-182, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27774659

ABSTRACT

This study aims to evaluate the effect of efflux pump modulators (EPMs) on the minimal inhibitory concentration (MIC) of fluconazole (FLZ) and voriconazole (VOR) in Malassezia furfur and Malassezia pachydermatis. The in vitro efficacy of azoles, in combination with EPMs (ie haloperidol-HAL, promethazine-PTZ and cyclosporine A-CYS), against 21 M. furfur from bloodstream infection patients and 14 M. pachydermatis from the skin of dogs with dermatitis, was assessed using a broth microdilution chequerboard analysis. Data were analysed using the model-fractional inhibitory concentration index (FICI) method. The MIC of FLZ and VOR of Malassezia spp. decreased in the presence of sub-inhibitory concentrations of HAL and/or PTZ. The synergic effect was observed only in strains with FLZ MIC≥128 µg/mL for M. furfur, FLZ MIC≥64 µg/mL for M. pachydermatis and VOR MIC≥4 µg/mL in both Malassezia spp. These results suggest that the drug efflux pumps are involved as defence mechanisms to azole drugs in Malassezia yeast. The synergism might be related to an increased expression of efflux pump genes, eventually resulting in azole resistance phenomena. Finally, the above FLZ and VOR MIC values might be considered the cut-off to discriminate susceptible and resistant strains.


Subject(s)
Antifungal Agents/pharmacology , Cyclosporine/pharmacology , Drug Resistance, Fungal , Genes, MDR , Haloperidol/pharmacology , Malassezia/drug effects , Promethazine/pharmacology , Animals , Dermatitis/microbiology , Dermatomycoses/blood , Dermatomycoses/microbiology , Dogs , Drug Synergism , Fluconazole/pharmacology , Humans , Microbial Sensitivity Tests , Skin/microbiology , Voriconazole/pharmacology
12.
Vet Microbiol ; 162(2-4): 800-805, 2013 Mar 23.
Article in English | MEDLINE | ID: mdl-23141297

ABSTRACT

The mechanisms involved in the establishment of the specific immune response against dermatophytes remain unknown. Polymorphonuclear neutrophils (PMNs) are recruited early during the infection process and participate in the elimination of dermatophytes. They could therefore be involved in the induction of the immune response during dermatophytoses by producing specific cytokines. The aim of this work was to assess the in vitro cytokine production by feline PMNs exposed to living arthroconidia from the dermatophyte species Microsporum canis or stimulated with either a secreted or a structural component of M. canis, the latter consisting of heat-killed arthroconidia. The levels of specific cytokines produced by PMNs were determined by capture ELISA and/or quantitative RT-PCR. Results showed that PMNs secrete TNFα, IL-1ß and IL-8 following exposure to M. canis living arthroconidia and stimulation with both a secreted component and heat-killed arthroconidia. The level of IL-8 mRNA was also increased in PMNs stimulated with M. canis living arthroconidia. In conclusion, infective M. canis arthroconidia induce the production of pro-inflammatory cytokines by feline PMNs that can be activated either by secreted or structural fungal components. Our results suggest that these granulocytes are involved in the initiation of the immune response against M. canis.


Subject(s)
Cat Diseases/immunology , Cat Diseases/microbiology , Cytokines/immunology , Dermatomycoses/veterinary , Microsporum/immunology , Neutrophils/immunology , Neutrophils/microbiology , Animals , Cat Diseases/blood , Cats , Cells, Cultured , Cytokines/biosynthesis , Cytokines/blood , Dermatomycoses/blood , Dermatomycoses/immunology , Dermatomycoses/microbiology , Enzyme-Linked Immunosorbent Assay , Female , Interleukin-1beta/biosynthesis , Interleukin-1beta/blood , Interleukin-1beta/immunology , Interleukin-8/biosynthesis , Interleukin-8/blood , Interleukin-8/genetics , Interleukin-8/immunology , Male , RNA, Messenger/blood , RNA, Messenger/genetics , Spores, Fungal , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/immunology
13.
Int J Dermatol ; 52(1): 46-52, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22512309

ABSTRACT

BACKGROUND: Systemic and focal infections caused by microorganisms have been known to induce or exacerbate psoriasis. Although the role of yeast species of the genus Malassezia in the pathogenesis of psoriasis is not fully understood, it is thought that these lipophilic yeasts may represent a triggering factor in the exacerbation of psoriatic lesions. OBJECTIVES: This study investigated the effects of Malassezia yeasts on serum Th1 and Th2 cytokines in patients with guttate psoriasis (GP) in order to define their role in the pathogenesis of psoriasis. METHODS: Fifty patients with GP and 29 clinically healthy individuals were included in the study. All samples consisted of scales and scrapings taken from the scalps, trunks, and upper limbs of both psoriasis patients and healthy subjects. Psoriasis patients and healthy subjects were grouped according to their positivity or negativity for Malassezia yeasts as ascertained by direct microscopy and/or culture. An enzyme-linked immunosorbent assay (ELISA) was used to measure serum levels of Th1 and Th2 cytokines in these groups. RESULTS: No significant differences in positivity for Malassezia yeasts were found between psoriatic skin and healthy skin in samples taken from different body sites. Serum interleukin-13 (IL-13) levels were significantly lower in the psoriasis group compared with the control group (P = 0.04). Levels of other cytokines did not differ significantly between the psoriasis and control groups. Mean levels of Th2 cytokines (IL-4, IL-10, IL-13), but not of Th1 cytokines (IL-2 and IFN-γ), were significantly lower in psoriasis patients positive for Malassezia yeasts compared with those negative for Malassezia yeasts and control subjects (P = 0.04, P < 0.001 and P = 0.01, respectively). CONCLUSIONS: The isolation of Malassezia yeasts from GP lesions does not necessarily mean that these species are pathogenic, but their downregulating effects on anti-inflammatory Th2 cytokines may contribute to the occurrence of GP.


Subject(s)
Cytokines/blood , Dermatomycoses/blood , Malassezia/isolation & purification , Psoriasis/blood , Th1 Cells/immunology , Th2 Cells/immunology , Adult , Aged , Dermatomycoses/pathology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Psoriasis/pathology
14.
PLoS One ; 7(4): e35374, 2012.
Article in English | MEDLINE | ID: mdl-22558145

ABSTRACT

The disease chytridiomycosis is responsible for declines and extirpations of amphibians worldwide. Chytridiomycosis is caused by a fungal pathogen (Batrachochytrium dendrobatidis) that infects amphibian skin. Although we have a basic understanding of the pathophysiology from laboratory experiments, many mechanistic details remain unresolved and it is unknown if disease development is similar in wild amphibian populations. To gain a better understanding of chytridiomycosis pathophysiology in wild amphibian populations, we collected blood biochemistry measurements during an outbreak in mountain yellow-legged frogs (Rana muscosa) in the Sierra Nevada Mountains of California. We found that pathogen load is associated with disruptions in fluid and electrolyte balance, yet is not associated with fluctuations acid-base balance. These findings enhance our knowledge of the pathophysiology of this disease and indicate that disease development is consistent across multiple species and in both laboratory and natural conditions. We recommend integrating an understanding of chytridiomycosis pathophysiology with mitigation practices to improve amphibian conservation.


Subject(s)
Chytridiomycota , Dermatomycoses/epidemiology , Dermatomycoses/physiopathology , Dermatomycoses/veterinary , Disease Outbreaks/veterinary , Ranidae/microbiology , Animals , Blood Chemical Analysis/veterinary , California/epidemiology , Dermatomycoses/blood , Principal Component Analysis , Ranidae/blood , Ranidae/physiology , Water-Electrolyte Balance/physiology
16.
Rev Cubana Med Trop ; 59(2): 119-26, 2007.
Article in Spanish | MEDLINE | ID: mdl-23427445

ABSTRACT

Cutaneous infection by histoplasmosis in Cuban HIV patients was researched. In a case series study, all HIV patients admitted to "Pedro Kouri" Institute from January 1st, 1992 to June 30th, 2003, who had been diagnosed with cutaneous histoplasmosis, were included. Of 44 patients with histoplasmosis, 52% (23 cases) developed the progressive disseminated form of histoplasmosis, which behaved as a subacute weakening disease. Young adults represented 56.5% and 82.6% were males mainly Caucasian (91.3%). Most of cases came from the Western provinces. Histoplasmosis was a marker disease in 39.1% of cases. CD4+ T-lymphocyte counting under 200 cell/mm3 was present in 78.9% of patients. Histoplasmosis seems to behave as an important marker disease for AIDs in seropositive patients. Serology was not the diagnosing method of choice for this cutaneous disease in AIDS patients.


Subject(s)
AIDS-Related Opportunistic Infections/pathology , Dermatomycoses/pathology , Histoplasmosis/pathology , AIDS-Related Opportunistic Infections/blood , AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/microbiology , Adult , Antibodies, Fungal/blood , Biopsy , CD4 Lymphocyte Count , Candidiasis/epidemiology , Comorbidity , Cuba/epidemiology , Dermatomycoses/blood , Dermatomycoses/diagnosis , Dermatomycoses/epidemiology , Dermatomycoses/microbiology , Ethnicity , False Negative Reactions , Female , Histoplasma/growth & development , Histoplasma/immunology , Histoplasmosis/blood , Histoplasmosis/epidemiology , Histoplasmosis/microbiology , Humans , Male , Middle Aged , Retrospective Studies , Skin Pigmentation , Staining and Labeling , Young Adult
17.
Biol Trace Elem Res ; 113(3): 273-80, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17194927

ABSTRACT

The purpose of this study was to determine the zinc levels in calves with trichophytosis and to research the importance of zinc for fungi. The sera of 20 calves with trichophytosis and 10 healthy calves were used in this study. Zinc levels of the sera were measured by the atomic absorption spectrophotometer method. Serum zinc levels of diseased and healthy animals were found to be 42.0+/-16.6 microg/dL and 75.8+/-5.9 microg/dL, respectively. Serum zinc levels of diseased calves were lower than healthy ones and this difference were found to be important statistically (p<0.001), whereas there is no statistical difference on the levels of lymphocyte, monocyte, granulocyte, erythrocyte, hemoglobin, hematocrit, and mean corpuscular volume between groups. These parameters were not influenced by low zinc levels.


Subject(s)
Spectrophotometry, Atomic/methods , Tinea/blood , Zinc/blood , Animals , Cattle , Dermatomycoses/blood , Erythrocyte Indices , Erythrocytes/metabolism , Hematocrit , Hemoglobins/metabolism , Lymphocytes/metabolism , Monocytes/metabolism
19.
Mycopathologia ; 158(1): 17-24, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15487315

ABSTRACT

Few studies are available about the participation of the immune response in the control or the development of Jorge Lobo's disease. Thus, the objective of the present study was to quantify macrophage and lymphocyte cytokines in the supernatant of cell cultures and in blood serum from patients with this disease. The study was conducted on 15 patients with the mycosis and on 15 healthy adult individuals (control group). Blood samples were collected in order to obtain serum and mononuclear cells. Monocytes were cultured for 24 h in the presence or absence of LPS and L. loboi, and lymphocytes were cultured for 48 h in the presence or absence of PHA and L. loboi. Cytokines IL-1beta, TNF-alpha and IL-6 were quantified by ELISA in the supernatants of monocyte cultures and in serum. Cytokines IL-2, IFN-gamma, IL-4 and IL-10 were quantified by FLISA in the supernatants of lymphocyte cultures and in serum. The quantification of the cytokines in the culture supernatant revealed a greater IL-4 and IL-6 production and lower IL-2 levels in patients compared to control. The production of IL-1beta, TNF-alpha, IL-10 and INF-gamma was similar in patients and controls. The mononuclear cells from patients with the non-localized form of the disease produced higher INF-gamma levels than those of patients with the localized form. The results suggest that patients with Jorge Lobo's disease show altered cytokine profiles represented by a predominance of the Th2 profile. However, further studies are needed to assess the participation of cytokines in the cell-fungus interaction in situ.


Subject(s)
Cytokines/immunology , Dermatomycoses/immunology , Fungi/immunology , Leukocytes, Mononuclear/immunology , Macrophages/immunology , Cytokines/blood , Dermatomycoses/blood , Enzyme-Linked Immunosorbent Assay , Humans , Lymphocyte Activation/immunology , Male , Middle Aged , Rural Population , Statistics, Nonparametric , Th2 Cells/immunology
20.
Int Arch Allergy Immunol ; 135(2): 93-100, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15345907

ABSTRACT

BACKGROUND: The opportunistic yeast Malassezia is considered to be one of the factors that can contribute to atopic eczema (AE). Elevated serum IgE levels, T-cell proliferation and positive skin prick test (SPT) and atopy patch test (APT) reactions to Malassezia are found among AE patients. METHODS: Sera from 127 AE patients, 14 patients with seborrheic dermatitis (SD) and 33 healthy controls were investigated for IgE and IgG4 to M. sympodialis extract and four recombinant Malassezia allergens; rMala s 1, rMala s 5, rMala s 6, and rMala s 9. In addition, IgG to the recombinant allergens was analyzed. The IgG and IgG4 levels were compared to IgE levels and in vivo reactions (SPT and APT) to Malassezia. RESULTS: AE patients with serum IgE levels >0.35 kU/l to M. sympodialis extract had significantly higher IgG4 levels to M. sympodialis extract than AE patients without detectable serum IgE to M. sympodialis extract, SD patients and healthy controls. Among the AE patients with and without detectable serum IgE to M. sympodialis extract, respectively, there were no differences in IgG4 levels between patients with positive or negative in vivo reactions to M. sympodialis extract. IgG4 to the rMala s allergens was almost exclusively found among patients with IgE to the same allergen. Within the four tested rMala s allergens, most IgG4 reactions were found to rMala s 6, an allergen with homology to cyclophilin. CONCLUSIONS: Elevated serum IgG4 to M. sympodialis extract accompanies elevated serum IgE to the extract. This is further confirmed by the association between IgG/IgG4 and IgE to recombinant Malassezia allergens.


Subject(s)
Antibodies, Fungal/blood , Dermatitis, Atopic/blood , Dermatitis, Atopic/immunology , Immunoglobulin E/blood , Immunoglobulin G/blood , Malassezia/immunology , Adolescent , Adult , Antigens, Fungal/immunology , Dermatomycoses/blood , Dermatomycoses/immunology , Female , Humans , Male , Middle Aged , Radioallergosorbent Test , Recombinant Proteins/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...